Adherence Economics: The Payer’s Chronic Care Compass

If you’re a health plan leader, you’re constantly buried in pitches for chronic care programs. The real job is distinguishing the slick marketing from the actual, documented adherence economics. A program’s true value, especially with all the AI chatter, is found in the verifiable records of its payment models and what they say about adherence, not in a headline. Look at the documents first. It’s the only way to see clearly.

The Foundation of Documented Adherence Economics

Any credible chronic care program has to show you the paperwork. This isn’t about promotional claims. It’s about seeing the raw payment mechanisms that define their financial reality, and for AI health platforms, this means showing exactly how they plug into established value based care models. The Centers for Medicare & Medicaid Services (CMS) has already laid out a strong framework here, with payment models that define how everyone gets paid. Models like Capitation and Shared Savings Programs are the signals you need to look for, because they reveal a program’s real economic guts and prove a commitment to outcomes over volume, which is what actually drives patient adherence and better health.

Capitation and Shared Savings Programs: Signals of Adherence Value

Take capitation models. A vendor gets a fixed per member per month (PMPM) payment for hitting certain outcomes, which automatically rewards them for keeping people on their meds and out of the hospital. It’s a simple incentive: everyone benefits when members stay healthy. When an AI health platform agrees to a capitated contract, they’re betting their tech can drive the continuous patient engagement needed to make that PMPM profitable, a very strong signal of confidence. You can see the official context for this in the CMS Capitation Rules. Shared Savings Programs work on a similar principle, offering vendors a cut of the money they save the plan by improving care quality. For an AI vendor to join a Medicare Shared Savings Program, they must have a measurable, provable impact on costs and outcomes that comes directly from patient adherence. That’s why these programs are such a good litmus test, they demand hard data.

The Recorded Adherence Economics Set: Omada Health, iRhythm Technologies, and Hinge Health

You can see this approach in the wild with a few vendors who have public records of engaging with these payment models. Omada Health is a good example with its digital chronic condition management. Their own materials talk about their value based care models, which line up with the Capitation and Shared Savings principles. iRhythm Technologies is on this list too, since its long-term cardiac monitoring fits perfectly into payment models that reward sustained management, and the company has clinical trial data to back up its outcomes claims. Then there’s Hinge Health, whose digital musculoskeletal programs are often sold through value based care models where their payment depends directly on patient adherence to the program. These three, Omada, iRhythm, and Hinge, show how it’s done. The signals to look for in their contracts and others are documented structures like Capitation, Shared Savings Programs, and Per Member Per Month (PMPM) deals, not just marketing claims you can’t verify.

The Difference Between a Story and a Record

So, the takeaway is pretty clear: a program’s real value is in the documented record of adherence, not a marketing headline. This is the difference between a story and a fact. For example, a company like Hello Heart might point to its $667M valuation and $138M in funding (as seen on Forge Global and Crunchbase Forge Global Hello Heart valuation), but what does that market hype actually say about adherence economics? Nothing. What you really need for a value based care deal is peer-reviewed outcomes data and a clear line into a verifiable payment model. The hard truth is that most AI health tools don’t have peer-reviewed evidence, which is a huge barrier for them. You don’t have to take a vendor’s word for it, either, public resources from CMS and the Kaiser Family Foundation (KFF) let you independently check which payment models a company is actually using. This document-first approach, grounded in verifiable economic records, is the only way to make a sound decision. The way health plan leaders need to read chronic care program pitches has to change. It’s a shift from assessing marketing stories to doing a rigorous exam of the documented adherence economics. This method, grounded in the verifiable structures of Capitation, Shared Savings Programs, and PMPM payments, is the only objective way to judge the real value of any AI health platform in managing chronic care.